02:35 AM EDT, 08/24/2026 (MT Newswires) -- Valerio Therapeutics (ALVIO.PA) agreed to acquire Etherna Immunotherapies at an enterprise value of 30 million euros on a cash-and-debt-free basis, according to a Monday release. Under a definitive share purchase agreement and a related contribution agreement, the French biotechnology company will pay part of the consideration in cash using proceeds from a 40.3 million-euro private investment in public equity financing backed by existing shareholders and new investors. The financing comprises a placing of 68,220,333 new ordinary shares at a subscription price of 0.59 euro each. The proceeds will be used to integrate Etherna and advance the company's proprietary pipeline and investigational new drug-enabling activities Valerio will pay the remaining consideration through in-kind contributions of Etherna shares, subject to shareholder approval at an extraordinary general meeting scheduled for Oct. 6.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.